Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Inclusion Criteria:

1. Have Type 2 Diabetes (T2D)
2. Have HbA1c ≥ 7.0% to ≤ 9.5%
3. Are naïve to insulin therapy and have not used oral or injectable antihyperglycemic (diabetes) medication for at least 90 days prior to screening
4. Are of stable weight for at least 90 days prior to screening
5. Have a Body Mass Index (BMI) ≥ 23.0 kilograms per meter squared (kg/m^2)

Exclusion Criteria:

1. Have Type 1 Diabetes (T1D)
2. Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening
3. Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
4. Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
5. Have an estimated glomerular filtration rate (eGFR) <15 milliliters/minute/1.73 meter squared (mL/min/1.73 m^2) as determined by the central laboratory
6. Have a prior or planned surgical treatment for obesity
7. Have New York Heart Association Functional Classification IV congestive heart failure
8. Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening
9. Have a known clinically significant gastric emptying abnormality
10. Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
11. Have any lifetime history of a suicide attempt
12. Had chronic or acute pancreatitis
13. Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2
14. Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.